Substituted (E)-N-(1-phenylethylidene)benzohydrazide analogs or (3-(5-chloro-2-hydroxyphenyl)-4-METHYL-1 H-pyrazol-1-YL)(3- (morpholinosulfonyl)phenyl)methanone, derivatives thereof, and related compounds are useful as inhibitors of lysine-specific histone demethylase, including LSD1. Synthetic methods for making the compounds pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1 (lysine-specific demethylase). A pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, and one or more of: (a) at least one agent known to increase histone demethylase activity (b) at least one agent known to decrease histone demethylase activity (c) at least one agent known to treat a disorder of uncontrolled cellular proliferation (d) at least one agent known to treat a neurodegenerative disorder (e) instructions for treating a neurodegenerative disorder or (f) instructions for treating a disorder associated with uncontrolled cellular proliferation.
